News

August 18, 2017August 18, 2017

Prostate Cancer Consortium Partners with Tech Company Tempus for Trial Examining DNA Abnormalities

The Prostate Cancer Clinical Trials Consortium (PCCTC) has partnered with technology company Tempus to advance its Phase 2 clinical trial to identify the most effective treatment for prostate cancer in patients with genomic evidence ... Read more

August 17, 2017August 17, 2017

Mutations May Cause Prostate Cancer Patients to Become Resistant to BET Inhibitors, Study Says

News

Mutations in the SPOP gene in prostate cancer are a reason patients often develop resistance to a class of treatment known as BET inhibitors, Mayo Clinic researchers report. This finding is in ... Read more

August 16, 2017August 16, 2017

Hormone Therapy Delay Fails to Decrease Prostate Cancer Patients’ Quality of Life, Study Reports

News

After treating a man for prostate cancer, doctors pay close attention to whether levels of the disease’s main biomarker begin rising — an indication that the cancer has returned. ... Read more

August 14, 2017

Cesium-131 Brachytherapy May Be Prostate Cancer Game-changer, Study Reports

News

About 161,360 new cases of prostate cancer will be diagnosed in the United States in 2017, according to the American Cancer Society. The usual treatment options are radiation or surgery, both ... Read more

August 7, 2017

BMS and Clovis to Study Opdivo, Rubraca Combo Treatment in Prostate, Other Cancers

News

Bristol-Myers Squibb and Clovis Oncology will collaborate to assess the combination of Opdivo (nivolumab) and Rubraca (rucaparib) in Phase 2 and 3 clinical studies in patients with different cancer types, ... Read more

August 4, 2017August 4, 2017

Amgen Asks FDA to Expand Prolia’s Approval to Include an Additional Osteoporosis Condition

News

Amgen has asked the U.S. Food and Drug Administration to expand its approval of the bone-building therapy Prolia (denosumab) to include an additional osteoporosis condition. The initial authorization covered men with metastatic prostate cancer who ... Read more

August 2, 2017

FDA Accepts Marketing Application for Churchill’s Yonsa Microsize Tablets for Advanced Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Yonsa (abiraterone acetate) ultramicrosize tablets for the treatment of castration resistant prostate cancer that ... Read more

August 1, 2017

Minomic Launches U.S. Study of MiCheck Prostate Cancer Screening Test

News

Minomic International, an Australian immuno-oncology company, has initiated a prospective trial of its MiCheck Prostate Cancer Screening Test in the United States to further verify the technology’s accuracy and ... Read more

July 21, 2017July 21, 2017

Active Surveillance May Increase Likelihood of Adverse Outcomes in Low-Volume Intermediate-Risk Prostate Cancer

News

Active surveillance may expose men with intermediate-risk prostate cancer to adverse outcomes that could be avoided by immediate intervention, according to the findings of a large cohort study. The ... Read more

July 20, 2017

A Vasectomy Does Not Increase Risk of Prostate Cancer, Mayo Clinic Study Reports

News

No association between vasectomy and any form of prostate cancer showed up in a review of research and an analysis of factors across studies, Mayo Clinic researchers reported. This ... Read more